Edward J. Kaplan
Board Certified Radiation Oncologist
ekaplan@entotherapy.com
Edward J. Kaplan is a Board Certified Radiation Oncologist and the founder of Microspherix LLC. He received his medical degree from Albany Medical College and performed his internship at Beth Israel Medical Center in New York. He did his radiation oncology residency at Mt. Sinai in New York. At that time Mt. Sinai was the only hospital in New York City performing prostate implants. Dr. Kaplan used this as an opportunity to learn the procedure before most of his peers.
After completing his residency in radiation oncology at Mt. Sinai, Dr. Kaplan joined the staff of Fox Chase Cancer Center in Philadelphia where he completed his research fellowship. While there, he trained under Dr. Gerald Hanks, a highly respected leader in radiotherapy for prostate cancer.
Following his fellowship, Dr. Kaplan joined the faculty at Cornell University Medical College, where served as an assistant professor in radiation oncology. During his tenure at Cornell’s New York Hospital, he conducted extensive cancer research, lectured, and wrote scientific articles. In addition, he served on the medical school’s admissions committee and his department’s residency committee.
In 1996, Kaplan, his wife Zerlina and their children moved from New York City to Florida. It was the natural choice. Here, they could enjoy a more family-friendly lifestyle, and it was already home to extended family. Since establishing himself in Florida, he has pursued his interests in organized medicine, focusing on cancer-related organizations on the local and national level. He is a member of the American Society for Radiation Oncology, the American College of Radiology, the American Brachytherapy Society, the American College of Radiology, the American Medical Association, the Florida Medical Association and the Broward County Medical Association.
During the course of developing his practice here in South Florida, Kaplan was selected by his peers in 2008, 2009, 2010, 2011, 2012 and 2013 as one of Florida’s best doctors. Aside from his professional endeavors, he devotes time to his wife, Zerlina, and their three children –Jared, Brynna, and Trent. Kaplan’s other passion is working as a physician-scientist promoting the development of a host of breakthrough cancer treatments. He finds that many of the qualities that enabled him to move ahead with his patented medical innovations also served him well in establishing his cutting edge practice.
Dr. Kaplan has been working diligently on introducing a revolutionary new cancer treatment whereby pellets, the size of cupcake sprinkles, are administered by needle directly into tumors. This patented chemotherapy treatment, which Kaplan has dubbed entotherapy, was recently recognized by the State of Florida for its potential merit as a recipient of research funding by The National Cancer Institute. Each pellet carries time-released nanoparticles of chemotherapy drugs. Once injected into a tumor, the drug concentration is 1,000 times higher than if the drug had been injected intravenously or taken orally. The goal of treatment is to reduce side effects, rendering therapy more potent but at the same time non-toxic, open the door to a host of new treatment combinations and better patient outcomes.
In 2009, Dr Kaplan took his more than twenty years of experience in the medical field and opened the 1st Line Oncology in Coconut Creek, Florida. Here, he took a unique approach to cancer care by combining an exceptional team of professionals, the most advanced technology, and a beautiful facility, offering patients a supportive environment crucial to their recovery. His vision was to start with a blank canvas to create his ideal center, rather than retrofit an already existing facility.
Dr. Kaplan has taken that same approach with Microspherix LLC working diligently on introducing Entotherapy, a revolutionary new cancer treatment whereby pellets, the size of cupcake sprinkles, are administered by needle directly into tumors. This patented chemotherapy treatment was recently recognized by the State of Florida for its potential merit as a recipient of research funding by The National Cancer Institute. Each pellet carries time-released nanoparticles of chemotherapy drugs. Once injected into a tumor, the drug concentration is 1,000 times higher than if the drug had been injected intravenously or taken orally. The goal of treatment is to reduce side effects, rendering therapy more potent but at the same time non-toxic, open the door to a host of new treatment combinations and better patient outcomes.